In this study using real-world, insurance claims data, we compared insulin to other second-line T2DM medications (GLP-1 RAs, DPP-4Is, and SGLT2Is) with respect to incident HF risk. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.